| Outcome Measures: |
Primary: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 6 months|Number of participants with tight controlled diabetes melitus, Measurement of glycated hemoglobin, random blood sugar,fasting blood sugar, 6 months | Secondary: Number of participants with changing in liver stiffness measurement (LSM in kPa) measured by vibration-controlled transient elastography, Fibroscan before and after 6 months duration of treatment, 6 months|Number of participants with changing Liver and spleen size, Abdominal ultrasound, 6 months|Number of participant with changing in inflammatory biomarkers, Measurement of Monocyte to high-density lipoprotein cholesterol ratio Neutrophil to lymphocyte ratio Platelet to lymphocyte ratio Lymphocyte to monocyte ratio Neutrophil-percentage-to-albumin ratio, 6 months
|
